SciELO - Scientific Electronic Library Online

 
vol.33 número2Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaDisease progression after R-CHOP treatment associated with the loss of CD20 antigen expression índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista Brasileira de Hematologia e Hemoterapia

versão impressa ISSN 1516-8484

Resumo

BUCHPIGUEL, Carlos Alberto. Current status of PET/CT in the diagnosis and follow up of lymphomas. Rev. Bras. Hematol. Hemoter. [online]. 2011, vol.33, n.2, pp.140-147. ISSN 1516-8484.  http://dx.doi.org/10.5581/1516-8484.20110035.

Lymphomas are a heterogeneous group of malignancies that have a distinct biological behavior according to the subtype and degree of differentiation. Adequate staging, which has a direct impact on prognosis, is essential to properly plan therapy. Structural cross-sectional imaging, such as computed tomography, has been the standard imaging tool to stage and monitor patients with lymphoma. However, molecular imaging such as positron emission tomography has shown complementary diagnostic and prognostic values. This review discusses the current value of positron emission tomography imaging using 2-[fluorine-18]fluoro-2-deoxy-d-glucose in staging, restaging, monitoring and detecting relapse in Hodgkin's and non-Hodgkin lymphoma.

Palavras-chave : Lymph Nodes [radionuclide imaging]; Lymphoma [radionuclide imaging]; Positron-emission tomography; Fluorodeoxyglucose F18 [diagnostic use]; Lymphoma, Hodgkin's disease; Lymphoma, non-Hodgkin.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons